Author Contributions: Drs Marso and Rumsfeld had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Marso, House, Kennedy, Spertus, Rumsfeld.
Acquisition of data: House.
Analysis and interpretation of data: Marso, Amin, House, Kennedy, Spertus, Rao, Cohen, Messenger, Rumsfeld.
Drafting of the manuscript: Marso, House, Spertus, Rumsfeld.
Critical revision of the manuscript for important intellectual content: Marso, Amin, House, Kennedy, Spertus, Rao, Cohen, Messenger, Rumsfeld.
Statistical analysis: Marso, Amin, House, Kennedy, Rao.
Administrative, technical, or material support: Marso, House, Spertus, Messenger, Rumsfeld.
Study supervision: Marso, Rumsfeld.
Financial Disclosures: Dr Marso reported receiving research support from the American Diabetes Association, Amylin Pharmaceuticals, Boston Scientific, The Medicines Company, Volcano Corporation, and Terumo Corporation and serving as a consultant for Abbott Vascular, NovoNordisk, Volcano Corporation, and The Medicines Company. Mr House reported receiving consulting fees from Volcano Corporation. Dr Spertus reported receiving research funding from the National Institutes of Health, American College of Cardiology Foundation, American Heart Association, Amgen, Lilly, Bristol-Myers Squibb/Sanofi-Aventis, EvaHeart, and Cordis Corporation; receiving in-kind research support from Atherotech and Roche Diagnostics; serving as a consultant for United Healthcare, St Jude Medical, and Amgen; serving as a copyright holder of the Seattle Angina Questionnaire, the Kansas City Cardiomyopathy Questionnaire, and the Peripheral Artery Questionnaire; having equity ownership in Health Outcomes Sciences; and holding a patent on the PRISM technology, which executes multivariable models at the point of clinical care. Dr Rao reported receiving research support from Momenta Pharmaceuticals, Portola Pharmaceuticals, and Cordis Corporation and serving as a consultant for Bristol-Myers Squibb, Sanofi-Aventis, The Medicines Company, AstraZeneca, and Terumo Corporation. Dr Cohen reported receiving research support from The Medicines Company, Schering-Plough, Eli Lilly, and Daichi Sankyo; serving as a consultant for Schering-Plough and Eli Lilly; and receiving speaking honoraria from The Medicines Company, Eli Lilly, and St Jude Medical. Dr Messenger reported receiving research support from Pfizer, Medtronic, and Sanofi-Aventis. Dr Rumsfeld reported receiving salary support for the position of chief science officer for the NCDR. No other authors reported financial disclosures.
Funding/Support: This was an investigator-initiated study. The analytical work was performed at the Saint Luke's Mid America Heart Institute, an NCDR analytical center. There was no other additional financial or material support.
Disclaimer: The views expressed in this article represent those of the authors and do not necessarily represent the American College of Cardiology Foundation or the Society for Cardiac Angiography and Interventions, which cosponsor the National Cardiovascular Data Registry.
Additional Contributions: We thank Jose Aceituno, MS, for preparation of graphics and Joseph Murphy, MBA, for editorial assistance and publication coordination. Both are employees of Saint Luke's Hospital, Kansas City, Missouri. Neither received additional compensation for their contributions.